Genores Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 27-12-2024
- Paid Up Capital ₹ 0.50 M
as on 27-12-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Ebitda
- Net Worth -1.52%
(FY 2020)
- Total Assets %
(FY 2020)
About Genores Biotech
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Debayan Ghosh, Ineeyan Ariyaratnam, Manickam, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999MH2018PTC307155
- Company No.
307155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Genores Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ineeyan Ariyaratnam  | Director | 26-Mar-2019 | Current |
Debayan Ghosh  | Director | 26-Mar-2019 | Current |
| Manickam | Director | 26-Mar-2018 | Current |
| Soumitro Deb | Additional Director | 18-Mar-2020 | Current |
Financial Performance of Genores Biotech.
Genores Biotech Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 1.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Genores Biotech?
In 2020, Genores Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Beva Silicones Private LimitedActive 16 years 1 monthIneeyan Ariyaratnam and Manickam are mutual person
Epygen Biotech Private LimitedActive 13 years 4 monthsDebayan Ghosh, Ineeyan Ariyaratnam and 2 more are mutual person
Harris & Menuk Chemicals Private LimitedActive 9 years 10 monthsIneeyan Ariyaratnam and Manickam are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genores Biotech?
Unlock and access historical data on people associated with Genores Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genores Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genores Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
